The U.S. Food and Drug Administration (FDA) has accepted and filed for substantive scientific review the 22nd Century Group’s modified-risk tobacco product (MRTP) application for its Very Low Nicotine Content (VLNC) cigarettes under the proposed brand name of VLNTM.
22nd Century Group’s proposed VLNTM cigarettes are made with the company’s proprietary VLNC tobacco and, as a result, contain very low levels of nicotine.
“The FDA acceptance and filing of our MRTP application marks an important milestone in our mission to reduce the harm caused by smoking,” said Michael Zercher, chief operating officer of 22nd Century Group.
“We look forward to working with the FDA as the agency enters the next phase of its review process for our historic application.”